<DOC>
	<DOCNO>NCT01721902</DOCNO>
	<brief_summary>The primary objective study demonstrate feasibility safety intra-operative , intra-myocardial injection autologous CD133 positive bone marrow cell time coronary artery bypass graft ( CABG ) surgery patient chronic ischemic cardiomyopathy . Additionally , feasibility produce autologous CD133+ bone marrow stem cell assess . The investigator hypothesize collection sufficient number CD133+ cell bone marrow aspiration prior surgery , subsequent process intra-myocardial injection high purity cell follow completion CABG , feasible without significant adverse clinical consequence .</brief_summary>
	<brief_title>Stem Cell Implantation Patients Undergoing CABG</brief_title>
	<detailed_description>Coronary heart disease ( CHD ) lead cause death U.S. men woman age population rise prevalence diabetes ensure number person CHD continue increase next several decade . Two major factor contribute adverse outcome patient undergo coronary artery bypass grafting ( CABG ) surgery failure achieve complete revascularization , residual impairment leave ventricular function . In present study , investigator propose Phase I randomize double-blind study design assess feasibility safety autologous CD133+ cell patient refer CABG significant region viable non-revascularizable myocardium and/or significant LV systolic dysfunction likely improve conventional coronary revascularization . Autologous CD133+ bone marrow progenitor cell harvest study subject time CABG , process injected patient ' myocardium prior completion CABG surgery . The test material consist autologous CD133+ cell . Since intra-myocardial injection per se could stimulate neovascularization , control group patient receive placebo injection carrier solution . Control subject thus identical procedure randomize autologous CD133+ cell injection . The three goal study follow : 1 . To demonstrate feasibility safety intra-operative , intra-myocardial injection autologous CD133+ bone marrow cell adult chronic ischemic cardiomyopathy associate impair leave ventricular function . 2 . To assess effect autologous CD133+ cell injection regional myocardial perfusion function compare paired magnet resonance scan obtain prior CABG 6 month post CABG . 3 . To assess effect autologous CD133+ stem cell injection symptom severity quality life 6 month CABG surgery .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>18 year age old Patients ischemic heart disease manifest Canadian class II great angina and/or New York Heart Association class II , III IV exercise intolerance AND undergone diagnostic coronary angiography demonstrate least 70 % diameter narrow least 2 major coronary artery branch least 50 % diameter narrowing leave main coronary artery . Left ventricular systolic dysfunction evaluate echocardiography LV angiography ( LV ejection fraction less equal 49 % ) . No contraindication exclusion ( see ) Willingness participate ability provide informed consent Contraindications magnetic resonance imaging . Need emergent revascularization . Need concomitant surgical procedure time CABG ( e.g . valve repair replacement , aneurysm resection , etc. ) . Hemodynamically unstable patient . Patients confirm transmural myocardial infarction within 4 week , and/or rise cardiac biomarker protein ( i.e . troponin ) , and/or worsen ECG change . Prior CABG surgery . Stroke within 1 month prior plan CABG . Diagnosed human immunodeficiency virus ( HIV ) immune disorder immunosuppressive medication ( e.g . prednisone , cyclophosphamide , etanercept , etc . ) Organ dysfunction Contraindication bone marrow aspiration ( Thrombocytopenia &lt; 50.000 mm3 , INR &gt; 2.0 , use antiplatelet agent aspirin ) . Hemoglobin le 8g/dL , white blood cell count less 4,000/mm3 , absolute neutrophil count le 1500/mm3 Active infection Myelodysplastic syndrome ( MDS ) Significant cognitive impairment Any condition associate life expectancy le 6 month Patients know allergic reaction contraindication component CD133+ enrich cell Participation study concomitant study History severe ventricular tachyarrythmias Inability unwillingness provide write informed consent Positive serum pregnancy test</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>